The story of Sildenafil presents a intricate picture for shareholders. While the initial introduction generated massive profits, the expiration of its patent opened the door to generic competitors, dramatically eroding sales. This presents a unique risk for pharmaceutical companies banking on comparable blockbuster offerings, suggesting that a unqu

The story of Viagra, and its developer copyright, presents a complex case study for investors. Initially a blockbuster drug, generating billions in income, its patent expiration created a wave of lower-priced alternatives , significantly diminishing its position . While some businesses may try to capitalize on related treatments , the existing land